Perioperative Troponin is a Predictor of Both Short- and Intermediate-term Mortality Among Patients Undergoing Major Urologic Surgery.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
01 2019
Historique:
received: 22 02 2018
revised: 12 06 2018
accepted: 17 06 2018
pubmed: 12 9 2018
medline: 16 5 2019
entrez: 12 9 2018
Statut: ppublish

Résumé

To determine whether a positive troponin is a predictor of intermediate- and long-term mortality in patients undergoing major urologic surgeries at our institution. This is a retrospective analysis of patients undergoing major urologic surgery at the Cleveland Clinic from 2010-2015. Patients were stratified by the presence and maximum value of troponin blood-draw, if performed within 30 days of surgery. Survival analysis was performed using Kaplan-Meier function (univariate) and Cox regression analysis (continuous) to assess mortality risk. Within 30 days of surgery, 1305 (15.5%) patients a troponin drawn, and 304 (3.6%) of them had an abnormal troponin level (>0.01 ng/mL). Patients with positive troponin drawn for cause within 30 days of surgery had a significantly decreased overall survival at 5 years of 70.6% (95% CI 62.6, 77.2) when compared to patients with negative troponin (81.7% [95% CI 77.4, 85.3]) and no troponin drawn (90.4% [95% CI 89.0, 91.6]). For cause serum troponin blood draw and peak levels demonstrated a positive correlation with all-cause mortality in patients undergoing major urologic surgeries Prospective studies are needed to better understand the utility of postoperative troponin as predictive marker of mortality.

Identifiants

pubmed: 30201299
pii: S0090-4295(18)30913-0
doi: 10.1016/j.urology.2018.06.060
pii:
doi:

Substances chimiques

Troponin I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-113

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Yaw A Nyame (YA)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: nyamey@uw.edu.

Benjamin Abelson (B)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Abhinav Khanna (A)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Venu Menon (V)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Eric A Klein (EA)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Howard B Goldman (HB)

Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH